Publication
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerMyeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusionscivic_curation1.00
- drugDasatinibcivic_curation1.00
- drugMasitinibcivic_curation1.00
- drugMidostaurincivic_curation1.00
- drugNilotinibcivic_curation1.00
- drugPonatinibcivic_curation1.00
- drugSorafenibcivic_curation1.00
- drugSunitinibcivic_curation1.00
- genePDGFRAcivic_curation1.00
- variantPDGFRA Fusioncivic_curation1.00
- variantPDGFRA T674Icivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24407160
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PDGFRA Fusion1 | ||||||||
| Dasatinib + Masitinib + Midostaurin + Nilotinib + Ponatinib + Sorafenib + SunitinibSubstitutes | Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene FusionsALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1777In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib: 0.1-0.2nM, sorafenib: 0.1-0.2nM, masitinib: 0.2-0.5nM, nilotinib: 0.1-1… (full text at CIViC) PMID 24407160 · Sadovnik et al., 2014 · Open in CIViC | civic |
| PDGFRA Fusion + PDGFRA T674I1 | ||||||||
| Ponatinib | Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene FusionsALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1779Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Strong inhibitory … (full text at CIViC) PMID 24407160 · Sadovnik et al., 2014 · Open in CIViC | civic |
| PDGFRA Fusion + PDGFRA D842V1 | ||||||||
| Dasatinib + Imatinib + Masitinib + Nilotinib + Sorafenib + SunitinibSubstitutes | Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene FusionsALIAS | Predictive | D | Supports Resistance | 3 | submitted | EID13087Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Cells expressing D… (full text at CIViC) PMID 24407160 · Sadovnik et al., 2014 · Open in CIViC | civic |